Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | DGKA | P23743 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | PAM | P19021 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | P2RY10 | O00398 | 2/20 | 0.43 |
| ▸ | GPR174 | Q9BXC1 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL598299 | 1.00 | LMNA (0.50) | LMNAMAPTDGKAALDH1A1PAM | |
| SCHEMBL598488 | 1.00 | LMNA (0.50) | LMNAMAPTDGKAALDH1A1PAM | |
| SCHEMBL9665651 | 1.00 | LMNA (0.50) | LMNAMAPTDGKAALDH1A1PAM | |
| SCHEMBL9664746 | 1.00 | LMNA (0.50) | LMNAMAPTDGKAALDH1A1PAM | |
| SCHEMBL599360 | 1.00 | LMNA (0.50) | LMNAMAPTDGKAALDH1A1PAM | |
| SCHEMBL28031745 | 0.98 | MAPT (0.49) | LMNAMAPTDGKAALDH1A1PAM | |
| SCHEMBL29431881 | 0.98 | MAPT (0.49) | LMNAMAPTDGKAALDH1A1PAM | |
| SCHEMBL3283798 | 0.98 | MAPT (0.47) | LMNAMAPTDGKAALDH1A1PAM | |
| SCHEMBL598924 | 0.98 | MAPT (0.47) | LMNAMAPTDGKAALDH1A1PAM | |
| SCHEMBL15649495 | 0.87 | LMNA (0.53) | LMNAMAPTDGKAALDH1A1PAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1948199-B1 | PHARMACEUTICAL COMPOSITIONS FOR THE ADMINISTRATION OF APTAMERS | IDEXX LAB INC (US) | 2015-08-12 | — | — | EP | disclosed |
| EP-1960415-B1 | Phospholipid gel compositions for delivery of aptamers and methods of treating conditions using same | IDEXX LAB INC (US) | 2015-03-04 | — | — | EP | disclosed |
| US-8293253-B2 | Compositions for controlled delivery of pharmaceutically active compounds | IDEXX LABORATORIES, INC. (US) | 2012-10-23 | — | — | US | disclosed |
| US-8114440-B2 | Pharmaceutical compositions for the administration of aptamers | IDEXX LABORATORIES INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-8017159-B2 | Phospholipid gel compositions for delivery of aptamers and methods of treating conditions using same | IDEXX LABORATORIES, INC. (US) | 2011-09-13 | — | — | US | disclosed |
| US-20100240741-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE ADMINISTRATION OF APTAMERS | IDEXX LABORATORIES, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| US-20100204303-A1 | Pharmaceutical Compositions for Administering Oligonucleotides | IDEXX LABORATORIES, INC. (US) | 2010-08-12 | — | — | US | disclosed |
| US-7754679-B2 | Pharmaceutical compositions for the administration of aptamers | IDEXX LABORATORIES, INC. (US) | 2010-07-13 | — | — | US | disclosed |
| EP-2197454-A1 | PHARMACEUTICAL COMPOSITIONS FOR ADMINISTERING OLIGONUCLEOTIDES | IDEXX Laboratories Inc (US) | 2010-06-23 | — | — | EP | disclosed |
| WO-2009042625-A1 | PHARMACEUTICAL COMPOSITIONS FOR ADMINISTERING OLIGONUCLEOTIDES | IDEXX LABORATORIES, INC. (US) | 2009-04-02 | — | — | WO | disclosed |
| EP-1960415-A2 | PHOSPHOLIPID GEL COMPOSITIONS FOR DELIVERY OF APTAMERS AND METHODS OF TREATING CONDITIONS USING SAME | IDEXX Laboratories Inc (US) | 2008-08-27 | — | — | EP | disclosed |
| EP-1948199-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE ADMINISTRATION OF APTAMERS | IDEXX Laboratories Inc (US) | 2008-07-30 | — | — | EP | disclosed |
| EP-1804771-A2 | COMPOSITIONS FOR CONTROLLED DELIVERY OF PHARMACEUTICALLY ACTIVE COMPOUNDS | IDEXX LABORATORIES, INC. (US) | 2007-07-11 | — | — | EP | disclosed |
| WO-2007058800-A2 | PHOSPHOLIPID GEL COMPOSITIONS FOR DELIVERY OF APTAMERS AND METHODS OF TREATING CONDITIONS USING SAME | IDEXX LABORATORIES INC. (US) | 2007-05-24 | — | — | WO | disclosed |
| WO-2007058801-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE ADMINISTRATION OF APTAMERS | IDEXX LABORATORIES INC. (US) | 2007-05-24 | — | — | WO | disclosed |
| US-20070110827-A1 | Pharmaceutical compositions for the administration of aptamers | IDEXX LABORATORIES INC. | 2007-05-17 | — | — | US | disclosed |
| US-20070110775-A1 | Phospholipid gel compositions for delivery of aptamers and methods of treating conditions using same | IDEXX LABORATORIES INC. | 2007-05-17 | — | — | US | disclosed |
| US-20070111969-A1 | Pharmaceutical compositions for the administration of aptamers | IDEXX LABORATORIES INC. | 2007-05-17 | — | — | US | disclosed |
| WO-2006050002-A2 | COMPOSITIONS FOR CONTROLLED DELIVERY OF PHARMACEUTICALLY ACTIVE COMPOUNDS | IDEXX LABORATORIES, INC. (US) | 2006-05-11 | — | — | WO | disclosed |
| US-20060093632-A1 | Compositions for controlled delivery of pharmaceutically active compounds | IDEXX LABORATORIES, INC. | 2006-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060093632-A1 | Compositions for controlled delivery of pharmaceutically active compounds | LIPA, CEL, LPXN | LMNA 1207/4885MAPT 1702/4885DGKA 2585/4885 |
| US-20100240741-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE ADMINISTRATION OF APTAMERS | PHOSPHO1, SGMS1, PCYT1A | LMNA 576/4885MAPT 1126/4885DGKA 1080/4885 |
| US-20070111969-A1 | Pharmaceutical compositions for the administration of aptamers | PHOSPHO1, SGMS1, PCYT1A | LMNA 576/4885MAPT 1126/4885DGKA 1080/4885 |
| US-20100204303-A1 | Pharmaceutical Compositions for Administering Oligonucleotides | SLCO2A1, SLCO1A2, SLCO2B1 | LMNA 2767/4885MAPT 1162/4885DGKA 3560/4885 |
| US-20070110827-A1 | Pharmaceutical compositions for the administration of aptamers | PHOSPHO1, SGMS1, PCYT1A | LMNA 576/4885MAPT 1126/4885DGKA 1080/4885 |
| US-20070110775-A1 | Phospholipid gel compositions for delivery of aptamers and methods of treating conditions using same | ANXA6, ANXA2, PLTP | LMNA 542/4885MAPT 2973/4885DGKA 744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.